15.63
+1.16(+8.02%)
Currency In USD
| Previous Close | 14.47 |
| Open | 14.47 |
| Day High | 15.69 |
| Day Low | 14.2 |
| 52-Week High | 18.31 |
| 52-Week Low | 2.21 |
| Volume | 1.42M |
| Average Volume | 1.05M |
| Market Cap | 1.11B |
| PE | -4.16 |
| EPS | -3.76 |
| Moving Average 50 Days | 15.15 |
| Moving Average 200 Days | 10.24 |
| Change | 1.16 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $635.37 as of January 14, 2026 at a share price of $15.63. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $408.63 as of January 14, 2026 at a share price of $15.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 08, 2026 3:33 AM GMT
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the prici
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jan 07, 2026 9:05 PM GMT
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it i
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Jan 07, 2026 9:01 PM GMT
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain p